




Fig. 1A




Fig. 1B




Fig. 1C

Cetuximab ADCC PBMC : CAL27= 50:1




Fig. 2A

Cetuximab ADCC, PBMC : A431= 50:1




Fig. 2B

Cetuximab ADCC, NK92 CD16 v/v : A431 =3:1




Fig. 3A

Cetuximab ADCC, NK92 CD16 v/v : DLD-1 =3:1




Fig. 3B

Cetuximab ADCC, NK92 CD16 v/v : FaDu =3:1




Fig. 3C

Cetuximab ADCC, NK92 CD16 v/v : CAL27 =3:1




Fig. 3D




Fig. 4A




Fig. 4B




Fig. 5A




Fig. 5B




Fig. 6A




Fig. 6B




Fig. 7A




Fig. 7B




Fig. 8A




Fig. 8B